In a strategic move, Akoya Biosciences is currently evaluating an unsolicited buyout offer, following the announcement of merger proceedings with Quanterix earlier this year. Under the proposed acquisition deal, Quanterix stockholders are set to take the majority stake at 70%, while Akoya stockholders would retain 30% ownership. The arrangement would see Akoya operating as a wholly owned subsidiary of Quanterix, a decision aimed at bolstering Akoya’s initiatives in advancing spatial biology imaging. This potential buyout could have significant implications for the future direction and growth of Akoya Biosciences in the competitive biotech landscape. Stay tuned for more updates on this evolving situation.
Read more about this — here
